| Project/Area Number |
21659193
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Gastroenterology
|
|---|
| Research Institution | Osaka Medical College (2011)
Foundation for Biomedical Research and Innovation (2009-2010) |
|---|
Principal Investigator |
II Masaaki 大阪医科大学, 医学部, 講師 (10442922)
|
|---|
| Project Period (FY) |
2009 – 2011
|
| Project Status |
Completed (Fiscal Year 2011)
|
| Budget Amount *help |
¥2,610,000 (Direct Cost: ¥2,400,000、Indirect Cost: ¥210,000)
Fiscal Year 2011: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2010: ¥800,000 (Direct Cost: ¥800,000)
Fiscal Year 2009: ¥900,000 (Direct Cost: ¥900,000)
|
|---|
| Keywords | 胆道学 / 膵臓学 / 癌 / 細胞・組織 / ナノ材料 / 化学療法 |
|---|
| Research Abstract |
We made pirarubicin-conjugated PLGA-based nanoparticles(incorporation rate : 2.17μg/mg, average particle diameter : 890nm), and then the pirarubicin-conjugated PLGA(PrbPLGA group) or PLGA alone(PLGA group) was uptaken in cultured endothelial progenitor cells(EPCs). There were no significant differences of migration activity and proliferation activity between PrbPLGA group and PLGA group. When these nanoparticle-uptake EPCs were transplanted in tumor-bearing mice, the size of tumors were significantly reduced in PrbPLGA group than that in PLGA group compared with saline injected(control) group.
|
